GlassScriptPhysician profile
Douglas D Sankar
NPI 1134292220
$4,306.93
in general payments reported to CMS, 2019-2025
42 companies · $83.07 in 2025
The $83.07 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,593 · 2020: $969 · 2021: $227 · 2022: $376 · 2023: $40.67 · 2024: $17.98 · 2025: $83.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $141.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $277.40 | 2019-2020 | |
| Boston Scientific Corporation | $267.10 | 2021-2022 | |
| Genzyme Corporation | $266.11 | 2019-2020 | |
| Biogen, INC. | $260.89 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $260.69 | 2019-2020 | |
| Abbvie INC. | $244.55 | 2021-2025 | Ubrelvy |
| Acadia Pharmaceuticals INC | $233.89 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $167.27 | 2019-2020 | |
| Lundbeck LLC | $129.89 | 2019-2020 | |
| Allergan, INC. | $128.66 | 2020 | |
| Medtronic, INC. | $127.32 | 2022 | |
| Genentech USA, INC. | $126.42 | 2019-2020 | |
| Lilly USA, LLC | $126.32 | 2019-2020 | |
| Emd Serono, INC. | $123.01 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $120.31 | 2019 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Sankar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.